BioSpace News Archive

Transformative platform developed in partnership with leading healthcare systems enables real-time third-party risk management

These novel and valuable findings are based on the patented and patent-pending technology of GR, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and companion diagnostics.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman, President and CEO and Ms. Elizabeth Williams, CFO, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference which will be held from April 30 to May 1, 2019 in Toronto, Ontario.

Proceeds to provide support for development of Dance’s novel inhaled biologic products

A pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the study’s primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.

Visit D2 Booth 501, Asembia Specialty Pharmacy Summit, April 29 – May 2, 2019, Las Vegas, NV

Also provides an update on proposed acquisition of Solace Management Group Inc. and expected branding and distribution initiatives to follow.

New funds will support expansion initiatives in pharma and consumer sectors

Private Investment Firm to Lead Series A Funding Round Focused on Facilitating Alt Thirty Six’s Rapid Expansion and Technical Capabilities

The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation